Omnicell, Inc. (OMCL) EVP Robin Gene Seim Sells 9,780 Shares
Omnicell, Inc. (NASDAQ:OMCL) EVP Robin Gene Seim sold 9,780 shares of the company’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $48.97, for a total value of $478,926.60. Following the sale, the executive vice president now directly owns 55,896 shares in the company, valued at approximately $2,737,227.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Robin Gene Seim also recently made the following trade(s):
- On Tuesday, August 15th, Robin Gene Seim sold 15,109 shares of Omnicell stock. The stock was sold at an average price of $50.86, for a total value of $768,443.74.
Shares of Omnicell, Inc. (OMCL) traded down 1.11% during midday trading on Friday, hitting $49.10. 473,758 shares of the stock traded hands. The firm has a 50-day moving average price of $49.90 and a 200 day moving average price of $43.34. The stock’s market cap is $1.84 billion. Omnicell, Inc. has a one year low of $30.35 and a one year high of $52.70.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, July 27th. The company reported $0.02 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.02. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. The business had revenue of $180.90 million during the quarter, compared to analyst estimates of $174.08 million. During the same period in the previous year, the business posted $0.38 EPS. The company’s quarterly revenue was up 4.6% on a year-over-year basis. Analysts anticipate that Omnicell, Inc. will post $1.30 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/09/15/omnicell-inc-omcl-evp-robin-gene-seim-sells-9780-shares.html.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. acquired a new position in shares of Omnicell in the 1st quarter valued at about $125,000. LS Investment Advisors LLC boosted its holdings in shares of Omnicell by 136.3% in the 1st quarter. LS Investment Advisors LLC now owns 3,571 shares of the company’s stock valued at $145,000 after buying an additional 2,060 shares during the period. Oppenheimer Asset Management Inc. acquired a new position in shares of Omnicell in the 1st quarter valued at about $170,000. Turner Investments LLC acquired a new position in shares of Omnicell in the 2nd quarter valued at about $181,000. Finally, Riverhead Capital Management LLC boosted its holdings in shares of Omnicell by 76.3% in the 2nd quarter. Riverhead Capital Management LLC now owns 4,230 shares of the company’s stock valued at $182,000 after buying an additional 1,830 shares during the period. 96.35% of the stock is owned by institutional investors and hedge funds.
A number of analysts have recently weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $47.00 price objective (up previously from $43.00) on shares of Omnicell in a research report on Tuesday, June 13th. Dougherty & Co upped their price objective on Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a research report on Friday, July 28th. Craig Hallum upped their price objective on Omnicell from $46.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, July 28th. BidaskClub downgraded shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Finally, Zacks Investment Research upgraded shares of Omnicell from a “sell” rating to a “hold” rating in a research note on Tuesday, July 4th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $51.57.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.